Truist analyst Richard Newitter raised the firm’s price target on Procept BioRobotics to $72 from $63 and keeps a Buy rating on the shares. The company’s “solid” Q1 earnings beat checked multiple boxes, including utilization upside, increased guidance, gross margin outperformance, and improved operating expense leverage, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics sees FY24 revenue $213.5M, consensus $210.18M
- Procept BioRobotics reports Q1 EPS (51c), consensus (56c)
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Procept BioRobotics announces 12 scientific research presentations
- PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting